Somewhat Favorable Press Coverage Somewhat Unlikely to Impact IDEXX Laboratories (IDXX) Stock Price

News headlines about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.7702463830455 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

IDEXX Laboratories (NASDAQ IDXX) traded down $0.21 during trading hours on Thursday, hitting $159.78. 417,485 shares of the stock were exchanged, compared to its average volume of 702,380. IDEXX Laboratories has a twelve month low of $113.92 and a twelve month high of $173.01. The company has a market cap of $13,960.00, a PE ratio of 53.80, a P/E/G ratio of 2.42 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same period last year, the business earned $0.62 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. equities analysts expect that IDEXX Laboratories will post 3.24 earnings per share for the current fiscal year.

Several research analysts have issued reports on IDXX shares. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Monday, August 21st. Canaccord Genuity reiterated a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. Bank of America upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a report on Wednesday, August 23rd. Finally, Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $173.67.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total value of $8,171,280.00. Following the sale, the chairman now directly owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the sale, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock worth $16,686,200 over the last 90 days. Company insiders own 2.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact IDEXX Laboratories (IDXX) Stock Price” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/07/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-idexx-laboratories-idxx-stock-price.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply